Medtronic has launched the Valiant Navion thoracic stent graft system in Japan, following approval from the country’s Ministry of Health, Labour and Welfare (MHLW).
The graft system is for use for the repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD).
Previously, the device secured the US Food and Drug Administration (FDA) approval and the European CE-Mark.
Valiant Navion is based on the Valiant Captivia thoracic stent graft system and is designed to expand patient applicability.
Both the proximal covered CoveredSeal and proximal bare metal FreeFlo stent configurations are said to feature tip capture accuracy.
Medtronic aortic business vice-president and general manager John Farquhar said: “In just one year, the Valiant Navion system has achieved significant impact in expanding minimally invasive treatment options to patients globally.
“By designing a device with a global patient population in mind, we have ultimately broadened patient applicability and allowed for more patients to receive endovascular repair.”
Separately, the company launched the Patient Programmer technology for deep brain stimulation (DBS) therapy in the US.
The programmer uses a custom-configured Samsung mobile device to enable therapy management for more than 150,000 patients who received the company’s DBS implants.
It integrates Samsung Knox security technology to protect both the device and the patient.
The Patient Programmer consists of a programmer handset and a communicator, which links the implant to the programmer handset.
Patients can use the programmer to make changes to their therapy settings, turn the therapy on / off and check the neurostimulator’s battery by holding the communicator over the implanted device.
Furthermore, clinicians can coordinate with patients to modify DBS therapy settings between clinic visits.